|
2023 Journal Article A review of RRx-001: a late-stage multi-indication inhibitor of NLRP3 activation and chronic inflammationJayabalan, Nanthini, Oronsky, Bryan, Cabrales, Pedro, Reid, Tony, Caroen, Scott, Johnson, Aishwarya M., Birch, Natalia A., O’Sullivan, John D. and Gordon, Richard (2023). A review of RRx-001: a late-stage multi-indication inhibitor of NLRP3 activation and chronic inflammation. Drugs, 83 (5), 389-402. doi: 10.1007/s40265-023-01838-z |
|
2023 Conference Publication Case Study: Patient HL, Parkinson’s DiseaseMcCann, Emily, Lee, Soohyun, Coleman, Felicia, O'Sullivan, John and Nestor, Peter (2023). Case Study: Patient HL, Parkinson’s Disease. Cognition and Basal Ganglia Club, Brisbane, QLD Australia, March 2023. |
|
2023 Conference Publication Pareidolias as misperceptions in Lewy Body DisordersMcCann, Emily, Lee, Soohyun, Coleman, Felicia, O'Sullivan, John and Nestor, Peter (2023). Pareidolias as misperceptions in Lewy Body Disorders. Clem Jones Centre for Ageing and Dementia Research (CJCADR) Scientific Symposium, Brisbane, QLD Australia, 9 February 2023. |
|
2022 Conference Publication Update on TRIP: Therapy to reduce dementia risk in Parkinson’s disease proof of concept trialPourzinal, D., Bakker, A., Byrne, G.J., McMahon, K., O’Sullivan, J.D., Adam, R., Lehn, A., Copland, D., Yang, J.H., Au, T., Littleford, R., Chatfield, M., Pontone, G., Mari, Z. and Dissanayaka, N. (2022). Update on TRIP: Therapy to reduce dementia risk in Parkinson’s disease proof of concept trial. UQ Centre for Clinical Research HDR Symposium, Brisbane, QLD Australia, 24 November 2022. |
|
2022 Journal Article Semantic fluency deficits and associated brain activity in Parkinson’s disease with mild cognitive impairmentYang, Jihyun, McMahon, Katie L., Copland, David A., Pourzinal, Dana, Byrne, Gerard J., Angwin, Anthony J., O’Sullivan, John D. and Dissanayaka, Nadeeka N (2022). Semantic fluency deficits and associated brain activity in Parkinson’s disease with mild cognitive impairment. Brain Imaging and Behavior, 16 (6), 1-12. doi: 10.1007/s11682-022-00698-7 |
|
2022 Conference Publication LC-MS based urine metabolomic profiling indicate altered gut microbiome and host lipid metabolites in Parkinson's diseaseJewell, Shannon, Roper, Kerry, Woodhouse, Helen, Adam, Robert, O'Sullivan, John and Gordon, Richard (2022). LC-MS based urine metabolomic profiling indicate altered gut microbiome and host lipid metabolites in Parkinson's disease. Experimental Biology 2022 Meeting, Philadelphia, PA United States, 2-5 April 2022. Hoboken, NJ United States: John Wiley and Sons. doi: 10.1096/fasebj.2022.36.S1.R2928 |
|
2022 Conference Publication A Novel Role for Glucocerebrosidase 1 (GBA1) in Parkinson's DiseaseJayabalan, Nanthini, Roper, Katherine Kerry, Woodhouse, Helen M., Adam, Robert J., O'Sullivan, John D. and Gordon, Richard (2022). A Novel Role for Glucocerebrosidase 1 (GBA1) in Parkinson's Disease. Experimental Biology Meeting 2022, Philadelphia, PA United States, 2-5 April 2022. Hoboken, NJ United States: John Wiley and Sons. doi: 10.1096/fasebj.2022.36.S1.R5391 |
|
2022 Journal Article Caring for a loved one with Parkinson’s disease: the role of coping styles and relationship qualityZhang, Angeline, Mitchell, Leander K., Pachana, Nancy A., Yang, Ji Hyun J., Au, Tiffany R., Byrne, Gerard J., O’Sullivan, John D. and Dissanayaka, Nadeeka N. (2022). Caring for a loved one with Parkinson’s disease: the role of coping styles and relationship quality. International Psychogeriatrics, 34 (7) PII S1041610221002866, 1-8. doi: 10.1017/s1041610221002866 |
|
2022 Conference Publication Update on TRIP: Therapy to reduce dementia risk in Parkinson’s disease proof of concept trialPourzinal, D., Bakker, A., Byrne, G.J., McMahon, K., O’Sullivan, J.D., Adam, R., Lehn, A., Copland, D., Yang, J.H., Au, T., Littleford, R., Chatfield, M., Pontone, G., Mari, Z. and Dissanayaka, N. (2022). Update on TRIP: Therapy to reduce dementia risk in Parkinson’s disease proof of concept trial. UQ Neurosciences Symposium, Brisbane, QLD Australia, 26-27 September 2022. |
|
2021 Journal Article Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: Protocol for a phase 2, randomised, double-blind, placebo-controlled trialVivash, Lucy, Bertram, Kelly L, Malpas, Charles B, Marotta, Cassandra, Harding, Ian H, Kolbe, Scott, Fielding, Joanne, Clough, Meaghan, Lewis, Simon J G, Tisch, Stephen, Evans, Andrew H, O'Sullivan, John D, Kimber, Thomas, Darby, David, Churilov, Leonid, Law, Meng, Hovens, Christopher M, Velakoulis, Dennis and O'Brien, Terence J (2021). Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: Protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 11 (12) e055019, e055019. doi: 10.1136/bmjopen-2021-055019 |
|
2021 Conference Publication Using N-of-1 tests to identify responders to melatonin for sleep disturbance in Parkinson’s DiseaseNikles, J., Mitchell, G. K., Smith, S. S., McGree, J. M., McDonald, S., Poli, N., Senior, H., Tan, S., Dissanyaka, N., Ritchie, A. and O'Sullivan, J. D. (2021). Using N-of-1 tests to identify responders to melatonin for sleep disturbance in Parkinson’s Disease. Australian Clinical Trials Alliance conference, Sydney, NSW, Australia, November 2021. |
|
2021 Journal Article Anxiety disorders are associated with verbal memory impairment in patients with Parkinson’s disease without dementiaDissanayaka, Nadeeka N., Forbes, Elana J., Yang, Ji Hyun J., Pourzinal, Dana, O’Sullivan, John D., Mitchell, Leander K., Copland, David A., McMahon, Katie L. and Byrne, Gerard J. (2021). Anxiety disorders are associated with verbal memory impairment in patients with Parkinson’s disease without dementia. Journal of Neurology, 269 (3), 1600-1609. doi: 10.1007/s00415-021-10736-x |
|
2021 Conference Publication Therapy to reduce dementia risk in Parkinson’s disease (TRIP): Proof-of-concept protocolPourzinal, D., Bakker, A., Byrne, G.J., McMahon, K., O’Sullivan, J., Adam, R., Copland, D., Yang, J.H.J., Au, T., Littleford, R., Chatfield, M., Pontone, G., Mari, Z. and Dissanayaka, N. (2021). Therapy to reduce dementia risk in Parkinson’s disease (TRIP): Proof-of-concept protocol. Australia Dementia Forum 2021, Online, 31 May - 1 June 2021. |
|
2021 Journal Article Defining atypical anxiety in Parkinson's diseaseForbes, Elana J., Byrne, Gerard J., O'Sullivan, John D., Yang, Jihyun, Marsh, Rodney and Dissanayaka, Nadeeka N. (2021). Defining atypical anxiety in Parkinson's disease. Movement Disorders Clinical Practice, 8 (4), 571-581. doi: 10.1002/mdc3.13193 |
|
2021 Journal Article Neural correlates of attentional deficits in Parkinson’s disease patients with mild cognitive impairmentYang, Jihyun, Pourzinal, Dana, McMahon, Katie L., Byrne, Gerard J., Copland, David A., O’Sullivan, John D. and Dissanayaka, Nadeeka N. (2021). Neural correlates of attentional deficits in Parkinson’s disease patients with mild cognitive impairment. Parkinsonism and Related Disorders, 85, 17-22. doi: 10.1016/j.parkreldis.2021.02.009 |
|
2021 Journal Article Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE studyEvans, Andrew, Fung, Victor S. C., O'Sullivan, John D., Stell, Rick, White, Richard, Williams, David R., Femia, Samira and Onuk, Koray (2021). Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study. Clinical Parkinsonism and Related Disorders, 4 100075, 100075. doi: 10.1016/j.prdoa.2020.100075 |
|
2021 Conference Publication Investigating resting state functional connectivity in sub-phenotypes of mild cognitive impairment in Parkinson’s diseasePourzinal, D., Yang, J.H., Byrne, G.J., O’Sullivan, J.D., McMahon, K., Copland, D.A. and Dissanayaka, N. (2021). Investigating resting state functional connectivity in sub-phenotypes of mild cognitive impairment in Parkinson’s disease. Australia Dementia Forum 2021, Online, 31 May – 1 June 2021. |
|
2020 Conference Publication Therapy to reduce dementia risk in Parkinson’s disease (TRIP): proof-of-concept protocolPourzinal, D., Bakker, A., Byrne, G. J., McMahon, K., O'Sullivan, J., Adam, R., Copland, D., Yang, J. H. J., Au, T., Littleford, R., Chatfield, M., Pontone, G., Mari, G. and Dissanayaka, N. (2020). Therapy to reduce dementia risk in Parkinson’s disease (TRIP): proof-of-concept protocol. Herston Health Precinct Symposium 2020, Brisbane, QLD Australia, 7-11 December 2020. |
|
2020 Conference Publication Altered functional connectivity of the hippocampus in posterior-cortical subtype of cognitive impairment in Parkinson’s diseasePourzinal, D., Yang, J. H., Byrne, G. J., O'Sullivan, J. D., Mitchell, L. K., McMahon, K. L., Copland, D. A. and Dissanayaka, N. N. W. (2020). Altered functional connectivity of the hippocampus in posterior-cortical subtype of cognitive impairment in Parkinson’s disease. Australian Society for Medical Research Queensland Postgraduate Student Conference, Online, 11 November 2020. |
|
2020 Conference Publication Improving diagnosis and treatment of anxiety in Parkinson’s disease: IDATA-PD study updateDissanayaka, N., Byrne, G. J., Mitchell, L. K., O'Sullivan, J. D., Padmassini, A., White, E. X., Yang, J. H. J., Forbes, E., Thangavelu, K., Au, T., Lehn, A., Adam, R. and Pachana, N. A. (2020). Improving diagnosis and treatment of anxiety in Parkinson’s disease: IDATA-PD study update. Herston Health Precinct Symposium 2020, Brisbane, QLD Australia, 7-11 December 2020. |
